NASHVILLE, Tennessee — December 15, 2025 — Cencora, Inc. announced it has entered into a definitive agreement to acquire TPG’s equity interest in OneOncology, solidifying its ownership position in the physician-led national oncology platform. The transaction represents a significant milestone in Cencora’s pharmaceutical-centric growth strategy and marks the next phase of expansion for OneOncology, which supports independent community oncology and specialty practices across the United States. By deepening its investment, Cencora aims to enhance clinical innovation, technology-enabled services, and operational scale while preserving the platform’s physician-led and practice-independent model.
Science Significance
Although the transaction is not tied to a specific drug or clinical trial, its scientific relevance lies in strengthening the infrastructure that enables high-quality oncology care and research delivery. OneOncology supports a nationwide network of practices involved in evidence-based cancer treatment, clinical trials participation, and real-world data generation. By reinforcing the platform with additional capital and operational support, the acquisition helps accelerate access to innovative oncology therapies and research protocols in community settings. This integration enhances the ability of physicians to adopt new treatment standards efficiently, translating advances in cancer science into routine clinical practice.
Regulatory Significance
From a regulatory perspective, the transaction has implications for governance, compliance oversight, and quality management across a large oncology services network. Community oncology practices operate within strict federal and state regulatory frameworks, including drug handling, reimbursement compliance, clinical trial conduct, and patient safety standards. Cencora’s expanded ownership underscores the importance of maintaining robust compliance systems, quality assurance processes, and regulatory alignment as OneOncology continues to scale. The acquisition also reinforces continuity in oversight as TPG exits, ensuring that regulatory responsibilities remain clearly defined within a highly regulated healthcare environment.
Business Significance
Advertisement
Strategically, the acquisition strengthens Cencora’s position as a leading pharmaceutical solutions and services organization with deep reach into oncology care delivery. OneOncology has grown rapidly since its inception, now supporting 36 partner practices, more than 2,300 providers, and care for approximately 1.5 million patients across 645 sites nationwide. By acquiring TPG’s stake, Cencora consolidates its investment and aligns the platform more closely with its broader strategy focused on pharmaceutical access, specialty care services, and technology-enabled solutions. The transaction also builds on Cencora’s recent acquisitions, enhancing its ability to offer integrated services spanning distribution, clinical research, and practice support.
Patients’ Significance
For patients, the acquisition is expected to support greater access to high-quality oncology care in community settings, where many individuals prefer to receive treatment closer to home. Strengthening OneOncology’s platform enables practices to invest in advanced technologies, coordinated care models, and expanded service offerings, all of which contribute to improved patient experience and outcomes. By reinforcing the independence of community practices while providing enterprise-level support, the transaction helps ensure that patients benefit from innovative cancer care without the need to transition to hospital-based systems, often at a lower overall cost.
Policy Significance
At a policy level, the transaction aligns with broader healthcare objectives focused on preserving independent physician practices, expanding access to specialty care, and controlling system-wide costs. Community oncology models are increasingly viewed as essential to delivering value-based care while maintaining patient choice. The acquisition highlights how strategic investment can support care delivery reform, strengthen local healthcare infrastructure, and complement national efforts to improve oncology outcomes. It also reflects continued interest from large pharmaceutical services organizations in shaping how care is delivered within regulated frameworks.
Cencora’s agreement to acquire TPG’s equity interest in OneOncology represents a pivotal step in the evolution of community-based oncology care. By combining capital investment, operational expertise, and a commitment to physician-led governance, the transaction positions OneOncology to continue expanding its impact while maintaining independence and clinical excellence. For the cGxP.wire audience, the deal underscores how pharmaceutical industry consolidation and strategic ownership decisions play a critical role in shaping compliant, scalable, and patient-centered oncology ecosystems across the United States.
Source: OneOncology LLC. press release
